Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD), and orally bioavailable, brain penetrant and highly potent LRRK2 kinase inhibitors are in early stages of clinical testing. Detection of LRRK2 phosphorylation, as well as phosph...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Belén, Lara Ordóñez, Antonio Jesús, Fdez, Elena, Mutez, Eugénie, Comptdaer, Thomas, Leghay, Coline, Kreisler, Alexandre, Simonin, Clémence, Vandewynckel, Laurine, Defebvre, Luc, Destée, Alain, Bleuse, Séverine, Taymans, Jean-Marc, Chartier-Harlin, Marie-Christine, Hilfiker, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792036/
https://www.ncbi.nlm.nih.gov/pubmed/31527116
http://dx.doi.org/10.1042/BCJ20190315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792036/
https://www.ncbi.nlm.nih.gov/pubmed/31527116
http://dx.doi.org/10.1042/BCJ20190315

Ejemplares similares